Electroacupuncture Promotes Gastric Motility by Suppressing Pyroptosis via NLRP3/Caspase-1/GSDMD Signaling Pathway in Diabetic Gastroparesis Rats.
10.1007/s11655-024-3821-6
- Author:
Hao HUANG
1
;
Yan PENG
1
;
Le XIAO
1
;
Jing WANG
1
;
Yu-Hong XIN
1
;
Tian-Hua ZHANG
1
;
Xiao-Yu LI
1
;
Xing WEI
2
Author Information
1. College of Acupuncture-Moxibustion-Tuina and Rehabilitation, Hunan University of Chinese Medicine, Changsha, 410208, China.
2. College of Acupuncture-Moxibustion-Tuina and Rehabilitation, Hunan University of Chinese Medicine, Changsha, 410208, China. 004752@hnucm.edu.cn.
- Publication Type:Journal Article
- Keywords:
Nod-like receptor family pyrin domain-containing protein 3;
cysteinyl aspartate specific proteinase-1;
diabetic gastroparesis;
electroacupuncture;
gasdermin D;
pyroptosis
- MeSH:
Animals;
Electroacupuncture;
NLR Family, Pyrin Domain-Containing 3 Protein/metabolism*;
Pyroptosis;
Rats, Sprague-Dawley;
Caspase 1/metabolism*;
Gastroparesis/physiopathology*;
Signal Transduction;
Male;
Diabetes Mellitus, Experimental/physiopathology*;
Phosphate-Binding Proteins/metabolism*;
Gastrointestinal Motility;
Rats;
Intracellular Signaling Peptides and Proteins/metabolism*;
Diabetes Complications/physiopathology*;
Gasdermins
- From:
Chinese journal of integrative medicine
2025;31(5):448-457
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To investigate the mechanism of electroacupuncture (EA) in treating diabetic gastroparesis (DGP) by inhibiting the activation of Nod-like receptor family pyrin domain-containing protein 3 (NLRP3) inflammasome and pyroptosis mediated via NLRP3/cysteinyl aspartate specific proteinase-1 (caspase-1)/gasdermin D (GSDMD) signaling pathway.
METHODS:Forty Sprague-Dawley rats were randomly divided into 4 groups including the control, DGP model, EA, and MCC950 groups. The DGP model was established by a one-time high-dose intraperitoneal injection of 2% streptozotocin and a high-glucose and high-fat diet for 8 weeks. EA intervention was conducted at Zusanli (ST 36), Liangmen (ST 21) and Sanyinjiao (SP 6) with sparse-dense wave for 15 min, and was administered for 3 courses of 5 days. After intervention, the blood glucose, urine glucose, gastric emptying, and intestinal propulsive rate were observed. Besides, HE staining was used to observe histopathological changes in gastric antrum tissues, and TUNEL staining was utilized to detect DNA damage. Protein expression levels of NLRP3, apoptosis-associated speck-like protein containing CARD (ASC), pro-caspase-1, caspase-1 and GSDMD were measured by Western blot. Immunofluorescence staining was employed to assess the activity of GSDMD-N. Lactate dehydrogenase (LDH) levels were detected by using a biochemical kit.
RESULTS:DGP rats showed persistent hyperglycemia and a significant decrease in gastrointestinal motility (P<0.05 or P<0.01), accompanied by pathological damage in their gastric antrum tissues. Cellular DNA was obviously damaged, and the expressions of NLRP3, ASC, pro-caspase-1, caspase-1 and GSDMD proteins were significantly elevated, along with enhanced fluorescence signals of GSDMD-N and increased LDH release (P<0.01). EA mitigated hyperglycemia, improved gastrointestinal motility in DGP rats and alleviated their pathological injury (P<0.05). Furthermore, EA reduced cellular DNA damage, lowered the protein levels of NLRP3, ASC, pro-caspase-1, caspase-1 and GSDMD, suppressed GSDMD-N activity, and decreased LDH release (P<0.05 or P<0.01), demonstrating effects comparable to MCC950.
CONCLUSION:EA promotes gastrointestinal motility and repairs the pathological damage in DGP rats, and its mechanism may be related to the inhibition of NLRP3 inflammasome and pyroptosis mediated by NLRP3/caspase-1/GSDMD pathway.
